

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-9 (Canceled).

Claim 10 (Previously Presented): A method for treatment of a Central Nervous System (CNS) disease, comprising administering, to a subject suffering from a disease of the CNS, a conjugate comprising an active substance in an amount sufficient to treat said disease of the CNS, wherein the active substance is coupled directly or indirectly by a covalent bond to one of the following peptides: SynB1 (SEQ ID NO: 11) or SynB3 (SEQ ID NO: 12), and wherein said active substance is an active chemical molecule, and said disease of the CNS is selected from the group consisting of brain cancer, pain and meningitis.

Claim 11 (Previously Presented): A method for driving a substance across the Blood Brain Barrier (BBB) to the Central Nervous System (CNS), comprising:

preparing a conjugate comprising an active substance coupled directly or indirectly by a covalent bond to one of the following peptides: SynB1 (SEQ ID NO: 11) or SynB3 (SEQ ID NO: 12), wherein said active substance is an active chemical molecule in the treatment of the CNS;

administering said conjugate to a subject suffering from a disease of the CNS in an amount sufficient to drive said active substance across the BBB to the CNS; and

driving said active substance across the BBB to the CNS,

wherein said disease of the CNS is selected from the group consisting of brain cancer, pain, and meningitis.

Claim 12 (Previously Presented): The method of claim 10, wherein said active chemical molecule is selected from the group consisting of antitumoral agents, antibiotic agents and analgesic agents.

Claim 13 (Previously Presented): The method of claim 11, wherein said active chemical molecule is selected from the group consisting of antitumoral agents, antibiotic agents and analgesic agents.

Claims 14-15 (Cancelled).